All In Biotech

NDA 018705 · Pohl Boskamp

Nitrolingual

Nitroglycerin · Sublingual · Nitrate Vasodilator

Last checked: Nov 19, 2026Latest source record: Jul 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Oct 31, 1985

Approved uses

2

Original approval plus efficacy supplements

Registered trials

237

47 Phase 3, 10 recruiting

FAERS reports

42,231

34,551 serious, 5,606 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 29, 2026.

Nitroglycerin Lingual Spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin Lingual Spray is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease ( 1 ).

Mechanism: Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This eventually leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in vasodilatation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 10, 1997 Supplement 6 · Efficacy
  • Oct 31, 1985 Original approval · Type 3 - New Dosage Form
2 products under this application
  • NITROLINGUAL · NITROGLYCERIN 0.4MG/SPRAY · AEROSOL, SUBLINGUAL · Discontinued
  • NITROLINGUAL PUMPSPRAY · NITROGLYCERIN 0.4MG/SPRAY · SPRAY, METERED, SUBLINGUAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitroglycerin" as an intervention, any sponsor and status, largest first.

All 237 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea3,616
  • pain3,221
  • fatigue2,922
  • myocardial infarction2,820
  • nausea2,790
  • dizziness2,512
  • fall2,502
  • chest pain2,486
  • drug ineffective2,407
  • headache2,256
  • diarrhoea2,220
  • hypotension2,073

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004962
20051,094
2006924
2007712
2008929
20091,254
20101,415
20112,304
20121,749
2013887
20142,458
20151,505
20161,737
20171,805
20182,223
20192,444
20202,258
20212,287
20222,935
20232,904
20242,858
20252,755
20261,828

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nitrolingual (Nitroglycerin)

2024 spending

$27K

Beneficiaries

24

49 claims

Per beneficiary

$1,142

$33.67 per unit

View as table
YearSpending
2020$0
2021$30,249
2022$31,058
2023$36,119
2024$27,414

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,062 on PubMed

Sponsor: Pohl Boskamp · Also marketed as Nitrolingual Pumpspray

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.